Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Franklin Resources, Inc. and its principals Charles B. Johnson and Rupert H. Johnson, Jr. filed Amendment No. 2 to Schedule 13G on 08/01/2025 covering Innoviva, Inc. (INVA) common stock as of 06/30/2025.
- Ownership: 2,827,918 shares beneficially owned, equal to 4.5 % of outstanding shares.
- Control: Sole voting power – 2,583,688 shares; sole dispositive power – 2,827,918 shares; no shared voting or dispositive power.
- Threshold change: Item 5 confirms ownership has fallen to “5 percent or less,” indicating the group is now below the 5 % reporting threshold.
- Reporting persons: Franklin Resources (DE), Charles B. Johnson, and Rupert H. Johnson, Jr.; all file as holding company/control persons (Type HC, CO/IN).
- Purpose: Securities are held in the ordinary course by investment‐management subsidiaries; the filing states no intent to influence control of Innoviva.
The amendment mainly updates share counts and affirms that the institutional investor’s aggregate stake has decreased to a non-activist, sub-5 % level.